Variables | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
Hazard Ratio | 95% Cl | P | Hazard Ratio | 95% Cl | P | |
Age, years | 1.10 | 1.04 to 1.17 | < 0.001 | 1.10 | 1.03 to 1.16 | 0.003 |
T stage | ||||||
T0-T1 | Reference | |||||
T2-T4 | 2.45 | 0.94 to 6.33 | 0.065 | 1.75 | 0.91 to 6.43 | 0.078 |
N stage | ||||||
N0, Nx | Reference | |||||
N1 | 0.95 | 0.46 to 1.96 | 0.881 | |||
M stage | ||||||
M0, Mx | Reference | |||||
M1 | 2.07 | 1.10 to 3.89 | 0.024 | |||
Total CD3(+) T lymphocytes, cells/µL | ||||||
< 1203.05 | Reference | |||||
≥ 1203.05 | 0.45 | 0.20 to 1.01 | 0.053 | |||
CD3(+) CD4(+) T lymphocytes, cells/µL | ||||||
< 365.1 | Reference | Reference | ||||
≥ 365.1 | 0.36 | 0.18 to 0.74 | 0.006 | 0.30 | 0.14 to 0.65 | 0.002 |
CD4(+)/CD8(+) ratio | ||||||
< 1.10 | Reference | Reference | ||||
≥ 1.10 | 0.39 | 0.20 to 0.74 | 0.004 | 0.47 | 0.24 to 0.93 | 0.030 |
Total CD19(+) B lymphocytes, cells/µL | ||||||
< 45.83 | Reference | |||||
≥ 45.83 | 0.35 | 0.18 to 0.68 | 0.002 | |||
CD19(+) CD5(+) B lymphocytes, cells/µL | ||||||
< 5.76 | Reference | |||||
≥ 5.76 | 0.33 | 0.15 to 0.68 | 0.003 | |||
CD3(-)CD16(+)CD56(+) NK cells, cells/µL | ||||||
< 238.87 | Reference | Reference | ||||
≥ 238.87 | 1.73 | 0.91 to 3.30 | 0.095 | 2.29 | 1.14 to 4.62 | 0.020 |